Summary
An AI-powered platform accelerated the design and optimization of cyclic peptide therapeutics using generative models and physics-based simulations on high-performance cloud infrastructure. It enabled rapid target assessment, hit discovery, and iterative in silico optimization before experimental validation. The approach addressed drug targets that were difficult to reach with traditional modalities, improving the speed and quality of candidate development. This enhanced R&D productivity and expanded the addressable therapeutic landscape for biotech and pharmaceutical partners.